Valneva SE and Brazil’s Instituto Butantan have begun a ten‑municipality pilot program that will administer the single‑shot chikungunya vaccine IXCHIQ® to adults aged 18‑59. The initiative, which began on February 3 2026, aims for 20‑40 % coverage of the target population and will generate real‑world data on safety and effectiveness in an endemic setting.
IXCHIQ® received marketing approval from Brazil’s ANVISA in April 2025, making it the first chikungunya vaccine approved in an endemic country. The program follows the U.S. FDA’s suspension of the product’s license in August 2025, a setback that has limited the vaccine’s commercial reach in the largest market for the disease. By launching in Brazil, Valneva seeks to demonstrate the vaccine’s value in a high‑burden environment and support future regulatory and commercial opportunities worldwide.
The pilot is a strategic move for Valneva, which has faced financial challenges in recent quarters. The company reported an operating loss and negative adjusted EBITDA in its most recent earnings call, despite a 9 % year‑over‑year increase in total revenue. Valneva will donate up to 500,000 doses to the Brazilian Ministry of Health for the pilot, a gesture that underscores its commitment to public health while also creating a data set that could justify a broader commercial launch.
Juan Carlos Jaramillo, Valneva’s Chief Medical Officer, said the program “underscores our continued commitment to supporting global preparedness against the growing threat of chikungunya. Generating robust real‑world data in regions with active transmission remains critical and will reinforce the vaccine’s public health value.” Esper Kallas, Director of Instituto Butantan, added that the collaboration “has built a program that is both robust and regulatory‑compliant, enabling timely access to vaccination and reducing the significant public health burden posed by this arboviral disease.”
Brazil has reported over one million chikungunya cases between January 2019 and July 2024, with 263,502 cases and 246 deaths in 2024 alone. The pilot’s focus on a high‑burden country positions Valneva to capture a sizable market and to compete with other candidates such as Bavarian Nordic’s CHIKV VLP, whose rights have been acquired for Brazil by Eurofarma. Successful data collection could accelerate global approvals and open new revenue streams for Valneva.
The launch signals Valneva’s intent to pivot from a primarily research‑driven model to a more commercial focus, leveraging real‑world evidence to overcome regulatory hurdles and to justify pricing in markets that have been hesitant to adopt a new vaccine. The partnership with Instituto Butantan also strengthens Valneva’s local manufacturing and distribution capabilities, positioning the company to respond quickly to future outbreaks and to scale production if demand grows.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.